Language：English   Publishing type：Research paper (scientific journal)  

Acral lentiginous melanoma (ALM) is the most common melanoma subtype in non-Caucasians. Despite advances in cancer immunotherapy, current immune checkpoint inhibitors remain unsatisfactory for ALM. Hence, we conducted comprehensive immune profiling using single-cell phenotyping with reactivity screening of the T cell receptors of tumor-infiltrating T lymphocytes (TILs) in ALM. Compared with cutaneous melanoma, ALM showed a lower frequency of tumor-reactive CD8 clusters and an enrichment of regulatory T cells with direct tumor recognition ability, suggesting a suppressive immune microenvironment in ALM. Tumor-reactive CD8 TILs showed heterogeneous expression of coinhibitory molecules, including KLRC1 (NKG2A), in subpopulations with therapeutic implications. Overall, our study provides a foundation for enhancing the efficacy of immunotherapy in ALM.

DOI： 10.1126/scitranslmed.adk8832

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Acral and mucosal melanomas are more prevalent in Asians than in Caucasians, unlike cutaneous melanomas, which are predominant in Caucasians. Recent studies have suggested that non-Caucasian cutaneous melanomas responded less to immune checkpoint inhibitors, highlighting the need for genetic profiling across ethnicities. This study aimed to elucidate the genetic characteristics of Japanese melanomas, which is an under-researched topic. METHODS: Single-nucleotide variants, indels, and copy number alterations in 104 Japanese melanoma patients (37 cutaneous, 52 acral, and 15 mucosal) were analyzed using custom panel sequencing. RESULTS: Driver events were detected in 94% of the cases. Among cutaneous melanoma cases, 76% had BRAF mutations, and 8% had NRAS mutations. In acral melanoma, BRAF (9%), NRAS (17%), KRAS (8%), KIT (19%), and NF1 (7%) mutations were detected. Major driver mutations in mucosal melanoma were detected in NRAS, KRAS, NF1, PTEN, GNAQ, and KIT. The median tumor mutational burden across all melanoma types was 4.6 mutations/Mb, with no significant difference between the cutaneous and acral/mucosal types. Of the 21 patients with both primary and metastatic lesions, 11 showed distinct mutations in each. Potentially actionable mutations were detected in 58 patients in addition to BRAF V600E/K mutations in 31. CONCLUSIONS: This study highlights distinct genetic abnormalities and actionable alterations in Japanese melanoma patients. This suggests a lower tumor mutational burden in East Asian cutaneous melanoma, which may affect the efficacy of immune checkpoint inhibitors. The heterogeneity of driver mutations across and within individuals highlights the need for personalized treatment approaches.

DOI： 10.1002/cam4.70360

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Extramammary Paget's disease (EMPD) is a rare skin cancer with no standard treatment for advanced-stage disease. Although docetaxel-based chemotherapy is common, no standard treatment exists. Pembrolizumab is approved for solid tumors with a high tumor mutation burden (TMB) and/or high microsatellite instability, and nivolumab was approved in Japan in February 2024 for unresectable advanced or recurrent epithelial skin malignancies. However, there is a lack of real-world data regarding the efficacy of anti-programmed cell death protein 1 (PD-1) therapy for EMPD. We present the case details of three EMPD patients treated with anti-PD-1 therapy after docetaxel treatment, with TMB values of 17.8, 14.3, and 5.0 mut/Mb, respectively, and we review similar reported cases. Even in the cases with a high TMB, the response to anti-PD-1 therapy was not sufficient. Most cases involve second-line or later treatments, so further research is needed to determine the precise effectiveness of anti-PD-1 therapy as a first-line treatment.

DOI： 10.1111/1346-8138.17500

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Familial progressive hyperpigmentation with or without hypopigmentation (FPHH) is an autosomal dominant disorder characterized by widespread skin hyperpigmentation, café-au-lait spots, and hypopigmented circular macules, resulting from KITLG variants. KITLG, expressed by keratinocytes, binds to KIT on melanocytes, stimulating melanogenesis. Disturbances in the KITLG-KIT interaction result in diffuse hyperpigmentation in FPHH. However, the mechanisms behind hypopigmented macule formation remain unclear. This report presents a unique FPHH case in a patient with a novel KITLG mutation (Ser78Leu). Notably, the patient showed multiple hypopigmented macules and striae along the lines of Blaschko. Digital polymerase chain reaction analysis of the DNA from skin and blood tissues indicated a copy-neutral loss of heterozygosity at the KITLG locus, only in the hypopigmented macule. These findings suggest that the hypopigmented macules might result from revertant mosaicism. Conversely, café-au-lait spots do not follow the lines of Blaschko and can superimpose on the hypopigmented striae, indicating a distinct pathogenesis. This case contributes to the understanding of the genetic mechanisms in FPHH.

DOI： 10.1111/1346-8138.17459

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Cutaneous melanoma (CM) is the most common type in Caucasians, while acral melanoma (AM) and mucosal melanoma (MM), which are resistant to immunotherapies and BRAF/MEK-targeted therapies, are more common in East Asians. Genomic profiling is essential for treating melanomas, but such data are lacking in Japan. METHODS: Comprehensive genomic profiling data compiled in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) were analyzed. RESULTS: A total of 380 melanomas was analyzed, including 136 CM, 46 AM, 168 MM, and 30 uveal melanoma (UM). MM included conjunctival, sinonasal, oral, esophageal, anorectal, and vulvovaginal melanomas. No significant difference in the median tumor mutational burden (TMB) of CM (3.39 mutations/megabase), AM (2.76), and MM (3.78) was the key finding. Microsatellite instability-high status was found in one case. BRAF V600E/K was found in only 45 patients (12%). Key driver mutations in CM were BRAF (38%), NRAS (21%), NF1 (8%), and KIT (10%), with frequent copy number alterations (CNAs) of CDKN2A, CDKN2B, and MYC. AM was characterized by altered KIT (30%), NRAS (26%), and NF1 (11%) and CDKN2A, CDKN2B, CDK4, MDM2, and CCND1 CNAs. MM was characterized by altered NRAS (24%), KIT (21%), and NF1 (17%) and MYC, KIT, and CDKN2A CNAs, with differences based on anatomical locations. UM bore GNAQ or GNA11 driver mutations (87%) and frequent mutations in SF3B1 or BAP1. CONCLUSION: The distinct genomic profiling in Japanese patients, including lower TMB, compared to Caucasians, is associated with poorer treatment outcomes. This result underscores the need for more effective therapeutic agents.

DOI： 10.1007/s10147-024-02615-y

PubMed

researchmap

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC), an autosomal dominant disorder caused by variants in SUFU, is characterized by numerous infundibulocystic basal cell carcinomas (IBCCs). In this report, we present a possible case of mosaic MHIBCC. A 57-year-old woman underwent the removal of four papules on her face, which were diagnosed as IBCCs. Exome sequencing revealed a SUFU c.1022+1G>A mutation within the skin tumor. The same mutation was detected in her blood but at a lower allele frequency. TA cloning revealed that the allele frequency of the mutation in the blood was 0.07. Additionally, tumor assessment revealed loss of heterozygosity (LOH) in chromosome 10, including the SUFU locus. These results indicate the patient had mosaicism for the SUFU mutation in normal tissues, aligning with the mosaic MHIBCC diagnosis. This, combined with LOH, likely contributed to IBCC development. Mosaic MHIBCC may present with milder symptoms. However, it may still increase the risk of developing brain tumors and more aggressive basal cell carcinoma. The possibility of mosaicism should be investigated in mild MHIBCC cases, where standard genetic tests fail to detect SUFU germline variants.

DOI： 10.1111/1346-8138.17434

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/1346-8138.17401

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Epidermal keratinocytes, forming the outermost layer of the human body, serve as a crucial barrier against diverse external stressors such as ultraviolet radiation. Proper keratinocyte differentiation and effective responses to external stimuli are pivotal for maintaining barrier integrity. Heat is one such stimulus that triggers the synthesis of heat shock proteins (HSPs) when cells are exposed to temperatures above 42 °C. Additionally, activation of the transient receptor potential cation channel subfamily V member 1 (TRPV1) occurs at 42 °C. Here, we explore the interplay between TRPV1 signaling and HSP induction in human keratinocytes. Both heat and capsaicin, a TRPV1 agonist, induce expression of HSP27, HSP70, and HSP90 in keratinocytes. Interestingly, pharmacological inhibition of TRPV1 attenuates heat-induced HSP27 expression, but not that of HSP70 or HSP90. Furthermore, both heat and capsaicin stimulation result in distinct phosphorylation patterns of heat shock factor 1 (HSF1), with phosphorylation at serine 326 being a common feature. Notably, genetic manipulation to mimic dephosphorylation of HSF1 at serine 326 reduces HSP27 levels. Additionally, ΔNp63, a key regulator of epidermal differentiation, negatively modulates HSP27 expression independently of HSF1 phosphorylation status. While heat stimulation has no effect on ΔNp63 expression, capsaicin reduces its levels. The precise role of TRPV1 signaling in keratinocytes warrants further investigation for a comprehensive understanding of its impact on barrier function.

DOI： 10.1016/j.bbrc.2024.149817

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.17149

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

To study the inhibitory effects on microphthalmia-associated transcription factor (MITF)-related biological aspects in malignant melanomas (MMs) in the presence or absence of the low-molecular MITF specific inhibitor ML329, cell viability, cellular metabolic functions, and three-dimensional (3D) spheroid formation efficacy were compared among MM cell lines including SK-mel-24, A375, dabrafenib- and trametinib-resistant A375 (A375DT), and WM266-4. Upon exposure to 2 or 10 μM of ML329, cell viability was significantly decreased in WM266-4, SK-mel-24, and A375DT cells, but not A375 cells, in a dose-dependent manner, and these toxic effects of ML329 were most evident in WM266-4 cells. Extracellular flux assays conducted using a Seahorse bioanalyzer revealed that treatment with ML329 increased basal respiration, ATP-linked respiration, proton leakage, and non-mitochondrial respiration in WM266-4 cells and decreased glycolytic function in SK-mel-24 cells, whereas there were no marked effects of ML329 on A375 and A375DT cells. A glycolytic stress assay under conditions of high glucose concentrations also demonstrated that the inhibitory effect of ML329 on the glycolytic function of WM266-4 cells was dose-dependent. In addition, ML329 significantly decreased 3D-spheroid-forming ability, though the effects of ML329 were variable among the MM cell lines. Furthermore, the mRNA expression levels of selected genes, including STAT3 as a possible regulator of 3D spheroid formation, KRAS and SOX2 as oncogenic-signaling-related factors, PCG1a as the main regulator of mitochondrial biogenesis, and HIF1a as a major hypoxia transcriptional regulator, fluctuated among the MM cell lines, possibly supporting the diverse ML329 effects mentioned above. The findings of diverse ML329 effects on various MM cell lines suggest that MITF-associated biological activities are different among various types of MM.

DOI： 10.3390/cancers16020263

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.17070

PubMed

researchmap

Authorship：Corresponding author   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

DOI： 10.1111/1346-8138.16977

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The efficacy of combination therapy with an immune checkpoint inhibitor (ICI) and cytotoxic chemotherapeutic agents has been investigated in cancer, including melanoma. Before ICIs were introduced, dacarbazine or temozolomide (TMZ) were used to treat melanoma. Several studies using glioma or colorectal cancer cells showed that TMZ can increase the tumor mutation burden (TMB) and induce mismatch repair (MMR) deficiency associated with microsatellite instability (MSI). These could increase immunoreactivity to an ICI, but this has not been evaluated in melanoma cells. We investigated the effects of TMZ on MSI status and TMB in melanoma cells. To evaluate the TMB, we performed whole-exome sequencing using genomic DNA from the human melanoma cell lines Mel18, A375, WM266-4, G361, and TXM18 before and after TMZ treatment. Polymerase chain reaction amplification of five mononucleotide repeat markers, BAT25, BAT26, NR21, NR24, and MONO27, was performed, and we analyzed changes in the MSI status. In all cell lines, the TMB was increased after TMZ treatment (the change amount of TMB with ≤ 5% variant allele frequency [VAF] was 18.0-38.3 mutations per megabase) even in the condition without obvious cytological damage. MSI after TMZ treatment was not observed in any cells. TMZ increased TMB but did not change MSI status in melanoma cells.

DOI： 10.1111/1346-8138.16925

PubMed

researchmap

Language：English  

DOI： 10.1111/ijd.16771

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.16817

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

To study the molecular mechanisms responsible for inducing the spatial proliferation of malignant melanomas (MM), three-dimension (3D) spheroids were produced from several MM cell lines including SK-mel-24, MM418, A375, WM266-4, and SM2-1, and their 3D architectures and cellular metabolisms were evaluated by phase-contrast microscopy and Seahorse bio-analyzer, respectively. Several transformed horizontal configurations were observed within most of these 3D spheroids, and the degree of their deformity was increased in the order: WM266-4, SM2-1, A375, MM418, and SK-mel-24. An increased maximal respiration and a decreased glycolytic capacity were observed within the lesser deformed two MM cell lines, WM266-4 and SM2-1, as compared with the most deformed ones. Among these MM cell lines, two distinct cell lines, WM266-4 and SK-mel-24, whose 3D appearances were the closest and farthest, respectively, from being horizontally circular-shaped, were subjected to RNA sequence analyses. Bioinformatic analyses of the differentially expressed genes (DEGs) identified KRAS and SOX2 as potential master regulatory genes for inducing these diverse 3D configurations between WM266-4 and SK-mel-24. The knockdown of both factors altered the morphological and functional characteristics of the SK-mel-24 cells, and in fact, their horizontal deformity was significantly reduced. A qPCR analysis indicated that the levels of several oncogenic signaling related factors, including KRAS and SOX2, PCG1α, extracellular matrixes (ECMs), and ZO1 had fluctuated among the five MM cell lines. In addition, and quite interestingly, the dabrafenib and trametinib resistant A375 (A375DT) cells formed globe shaped 3D spheroids and showed different profiles in cellular metabolism while the mRNA expression of these molecules that were tested as above were different compared with A375 cells. These current findings suggest that 3D spheroid configuration has the potential for serving as an indicator of the pathophysiological activities associated with MM.

DOI： 10.3390/cells12050759

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1093/bjd/ljac009

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Complex interactions between keratinocytes and various cell types, such as inflammatory cells and stromal cells, contribute to the pathogenesis of chronic inflammatory skin lesions. In proinflammatory cytokine‒mediated disease settings, IL-9 plays a pathological role in inflammatory dermatitis. However, IL-9‒related mechanisms remain incompletely understood. In this study, we established tamoxifen-induced keratinocyte-specific IL-9RA-deficient mice (K14CRE/ERTIl9raΔ/Δ mice) to examine the role of IL-9 in multicellular interactions under chronic skin inflammatory conditions. Studies using an imiquimod-induced psoriasis-like model showed that K14CRE/ERTIl9raΔ/Δ mice exhibited a significantly reduced severity of dermatitis and mast cell infiltration compared with control K14WTIl9rafl/fl mice. Transcriptome analyses of psoriasis-like lesions showed that the level of peptide Y-Y (Pyy), a member of the neuropeptide Y family, was markedly downregulated in K14CRE/ERTIl9raΔ/Δ epidermis. Pyy blockade suppressed epidermal thickening and mast cell numbers in imiquimod-treated wild-type mice. Together with in vitro studies indicating that Pyy induced IL-9 production and chemotactic activity in bone marrow‒derived mast cells, these findings suggest that Pyy-mediated interplay between keratinocytes and mast cells contributes to psoriasiform inflammation. Further investigation focusing on the IL-9‒Pyy axis may provide valuable information for the development of new treatment modalities for inflammatory dermatitis.

DOI： 10.1016/j.jid.2022.06.021

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Malignant melanoma is one of the most malignant of all cancers. Melanoma occurs at the epidermo-dermal interface of the skin and mucosa, where small vessels and lymphatics are abundant. Consequently, from the onset of the disease, melanoma easily metastasizes to other organs throughout the body via lymphatic and blood circulation. At present, the most effective treatment method is surgical resection, and other attempted methods, such as chemotherapy, radiotherapy, immunotherapy, targeted therapy, and gene therapy, have not yet produced sufficient results. Since melanogenesis is a unique biochemical pathway that functions only in melanocytes and their neoplastic counterparts, melanoma cells, the development of drugs that target melanogenesis is a promising area of research. Melanin consists of small-molecule derivatives that are always synthesized by melanoma cells. Amelanosis reflects the macroscopic visibility of color changes (hypomelanosis). Under microscopy, melanin pigments and their precursors are present in amelanotic melanoma cells. Tumors can be easily targeted by small molecules that chemically mimic melanogenic substrates. In addition, small-molecule melanin metabolites are toxic to melanocytes and melanoma cells and can kill them. This review describes our development of chemo-thermo-immunotherapy based on the synthesis of melanogenesis-based small-molecule derivatives and conjugation to magnetite nanoparticles. We also introduce the other melanogenesis-related chemotherapy and thermal medicine approaches and discuss currently introduced targeted therapies with immune checkpoint inhibitors for unresectable/metastatic melanoma.

DOI： 10.3390/cancers14225588

PubMed

researchmap

Language：English  

DOI： 10.1111/ajd.13902

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The immunohistochemical evaluation of programmed death ligand 1 (PD-L1) is important for selecting treatments. Several antibodies are available for such evaluations, but data regarding the differences in the antibodies' positivity are limited in melanoma, particularly the acral and mucosal types. We investigated the differences in melanoma tissues' PD-L1 expression among the commonly used PD-L1 antibodies and then evaluated the relationship between PD-L1+ tumor cells and tumor-infiltrating lymphocytes (TILs). PATIENTS AND METHODS: We examined 56 primary lesions and 8 metastatic lymph node samples from 56 Japanese patients with melanoma (28 acral melanoma, 8 mucosal melanoma, 18 cutaneous melanoma, 2 unknown). Immunohistochemical staining was performed using three primary antibodies against PD-L1 (E1L3N, SP142, and 28-8). PD-L1-positive staining in tumor cells was defined as ≥ 1% expression. RESULTS: The positive rates were 25.0% for 28-8, 34.0% for E1L3N, and 34.0% for SP142 in 64 samples. The positive rates of acral melanoma were 10.7% for 28-8, 21.4% for E1L3N, and 21.4% for SP142. The positive rate of mucosal melanoma for which all three antibodies reacted was 12.5%. The positive rates of cutaneous melanoma were 55.6% for 28-8, 66.7% for E1L3N, and 66.7% for SP142. Significant relationships were observed among the PD-L1+ tumor cells, CD4+ TILs, and CD8+ TILs (p < 0.001). CONCLUSION: The staining results by E1L3N, SP142, and 28-8 antibodies were within the allowable range, although the positive rates by E1L3N and P142 were slightly higher than that of 28-8. CD4+ TILs and CD8+ TILs were quantitatively correlated with PD-L1-positive tumor cells.

DOI： 10.1007/s10147-022-02189-7

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.16331

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/cod.14001

PubMed

researchmap

Authorship：Corresponding author   Language：English  

DOI： 10.1111/1346-8138.16180

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

A sebaceous nevus is a congenital skin hamartoma caused by postzygotic HRAS or KRAS mosaic mutations. With age, affected individuals may develop secondary tumors within a sebaceous nevus. RAS mutations are harbored from the onset of sebaceous nevus, and further mutations can be expected to be required in order to explain the initiation of secondary tumors. However, genetic analyses of the secondary tumors have not been conducted. Herein, we describe the rare coexistence of a poroma and a trichoblastoma arising in a sebaceous nevus. This is the first report of an investigation of multiple genes in a secondary tumor in an SN. First, HRAS c.37G>C, which is the common mutation in sebaceous nevus, was detected in all three lesions (sebaceous nevus, poroma, and trichoblastoma). Next, to elucidate the potential second-hit mutations in the secondary poroma and trichoblastoma, we applied a panel sequencing for skin cancers that was newly developed in our institution. Our comparison of the mutational profile of 95 skin cancer-related genes in each of the three lesions newly revealed TP53 p.R158P in the poroma and NOTCH2 p.G329S in the trichoblastoma. TP53 p.R158P has been determined as a pathogenic mutation in other tumors, and NOTCH2 p.G329S was a novel mutation. We identified two novel mutations that may have contributed to the pathogenesis of the secondary tumor's development. The roles of the mutations remain unclear.

DOI： 10.1111/1346-8138.15919

PubMed

researchmap

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1684/ejd.2021.3997

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Barrier disruption and an excessive immune response in keratinocytes are now considered to have important roles in the pathophysiology of atopic dermatitis (AD). Furthermore, disturbed keratinocyte differentiation is considered to underlie AD. ΔNp63, a p53-like transcription factor, is a major regulator of keratinocyte differentiation. However, the functional significance of ΔNp63 in AD has not been clarified. OBJECTIVE: In this study, we aimed to investigate the influence of the type 2 inflammatory environment on ΔNp63 expression and AD-associated molecules regulated by ΔNp63 in keratinocytes. METHODS: The immunohistochemical expression profiles of ΔNp63 and AD-related molecules were evaluated in human skin tissue. The function of ΔNp63 in the regulation of AD-related molecules and the influence of the type 2 inflammatory environment on ΔNp63 expression were investigated using human primary keratinocytes. Expression of ΔNp63 was manipulated using the RNA interfering method. RESULTS: In healthy skin tissue, we observed an inverse expression pattern between ∆Np63 and some barrier-related proteins including filaggrin, caspase-14, claudin-1, and claudin-4. ΔNp63 regulated expression of these genes and proteins. In addition, production of IL-1β and IL-33, pro-inflammatory cytokines, was modulated by ΔNp63. Furthermore, prolonged IL-13 exposure increased the thickness of the three-dimensional culture of keratinocytes. IL-13 interfered with ΔNp63 downregulation during calcium-induced keratinocyte differentiation. IL-13 modulated some barrier-related and inflammation-related molecules, which were regulated by ΔNp63. CONCLUSIONS: We have shown that ΔNp63 modulated AD-related barrier and inflammatory molecules. In addition, ΔNp63 expression was affected by IL-4/IL-13. IL-13-ΔNp63 axis would integrate two major factors of AD pathogenesis: dysregulated barrier and inflammation.

DOI： 10.1002/iid3.427

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1684/ejd.2020.3861

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Melanogenesis is the biological and biochemical process of melanin and melanosome biosynthesis. Melanin is formed by enzymic reactions of tyrosinase family proteins that convert tyrosine to form brown-black eumelanin and yellow-red pheomelanin within melanosomal compartments in melanocytes, following the cascades of events interacting with a series of autocrine and paracrine signals. Fully melanized melanosomes are delivered to keratinocytes of the skin and hair. The symbiotic relation of a melanocyte and an associated pool of keratinocytes is called epidermal melanin unit (EMU). Microphthalmia-associated transcription factor (MITF) plays a vital role in melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes for promoting melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis. Diseases involving alterations of EMU show various forms of pigmentation phenotypes. This review introduces four major topics of melanogenesis cascade that include (1) melanocyte development and differentiation, (2) melanogenesis and intracellular trafficking for melanosome biosynthesis, (3) melanin pigmentation and pigment-type switching, and (4) development of a novel therapeutic approach for malignant melanoma by elucidation of melanogenesis cascade.

DOI： 10.3390/ijms21176129

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Treatment strategies for advanced melanoma are dramatically changing, due to immune-checkpoint inhibitors and BRAF/MEK inhibitors. Nevertheless, reliable serum markers for evaluation of treatment responses and the outcome are still limited. Some previous reports suggested that serum neuron-specific enolase (sNSE) may be a useful marker for melanoma; however, its usefulness is controversial. Moreover, NSE has not been examined in vitro by using melanoma cell lines. We retrospectively evaluated sNSE and serum lactate dehydrogenase (sLDH) levels at the initial diagnosis and during therapy in 33 melanoma patients of various stages. We analyzed the NSE concentrations in cell lysates and supernatants from melanoma cell lines by enzyme-linked immunosorbent assay. The median sNSE was significantly higher in stage IV patients compared with stages I/II and III (16.3, 12.7 and 12.1 ng/mL, respectively). sNSE was elevated in 20% (2/10) of stage III and 61.1% (11/18) of stage IV patients but not in stages I/II. sNSE and sLDH tended to correspond to the total tumor volume (P = 0.48 and 0.58; 95% confidence intervals, 0.005-0172 and 0.776-0.836, respectively). The coincidence rate of sNSE and sLDH in stage IV at the initial diagnosis was 11 of 18 (61.1%). Of the remaining patients, elevated sNSE but not sLDH was observed in five patients (27.8%) and elevated sLDH but not sNSE was observed in two (11.1%). Four of the five patients showing elevated sNSE and normal sLDH were of the mucosal type. NSE was detected in both supernatant and cell lysate of all four melanoma cell lines (0.30-237.32 ng/mL and 137-483.04 ng/mg, respectively). Two cell lines with a high supernatant NSE level contained many dead cells in the supernatant. The combination of sNSE and sLDH could contribute to the early detection of distant metastasis and disease condition evaluations for advanced melanoma patients.

DOI： 10.1111/1346-8138.15502

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.15509

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1684/ejd.2020.3778

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Neurofibromatosis type 1 (NF1) is a genodermatosis caused by heterozygous germ line variations in the NF1 gene. A second-hit NF1 aberration results in the formation of café-au-lait macules, cutaneous neurofibroma and plexiform neurofibroma (PNF). Mosaic NF1 (mNF1), caused by a postzygotic NF1 mutation, is characterized by localized or generalized NF1-related manifestations. Although NF1 and mNF1 are associated with pigmentary skin lesions, clinically recognizable melanocytic nevi that developed over PNF have not been reported. Here, we report the first case of multiple melanocytic nevi that developed on a giant café-au-lait macule and PNF. The PNF had biallelic NF1 deletions, a whole deletion of NF1 and a novel intragenic deletion involving exons 25-30. The deletions were not detected in the blood, which resulted in the diagnosis of mNF1. Furthermore, the nevus cells had not only biallelic NF1 deletions but also NRAS Q61R, a common mutation found in congenital melanocytic nevi. These analyses revealed the coexistence of the two different mosaic diseases, mNF1 and congenital melanocytic nevi. For a diagnosis of cases with atypical NF1-like symptoms, genetic analyses using blood and lesional tissues are useful and aid in genetic counseling.

DOI： 10.1111/1346-8138.15327

PubMed

researchmap

Language：English  

Angiomyolipoma (AML) is classified as a perivascular epithelioid cell neoplasm, mostly occurring in the kidney. Twenty percent of patients with renal AML have tuberous sclerosis complex (TSC) caused by germline variation in the TSC1 or TSC2 gene. In this paper, we report the first case of renal AML harboring somatic missense mutations of the TSC2 gene and concomitant copy-neutral loss of heterozygosity (CN-LOH). The patient presented with solitary renal AML and pulmonary lymphangiomyomatosis and without other findings suggestive of TSC. Exome sequencing analysis of the renal AML, however, identified a pathogenic somatic missense mutation in the TSC2 gene (NM_000548:c.5228G>A:p. R1743Q), although no other somatic mutation was detected. Furthermore, no germline mutation in TSC1 or TSC2 was detected. Interestingly, the mutant allele ratio was too high for a somatic heterozygous mutation without loss of heterozygosity (LOH). Furthermore, no copy number variation was detected around the TSC2 locus (16p13.3). To clarify the allelic status, we analyzed heterozygous single-nucleotide polymorphisms (SNPs) in chromosome 16. In these SNPs, an unbalanced allele ratio was accumulated inside the 16p13.3 region. These results suggested copy-neutral LOH (CN-LOH). Consequently, we concluded that the missense mutation of the TSC2 gene and CN-LOH of the TSC2 locus caused renal AML.

DOI： 10.1080/15384047.2019.1702406

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

AIM: To clarify the relationship between programmed cell death ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and clinicopathological variables. METHODS: We examined PD-L1 expression in tumor cells (TCs) and tumor infiltrating immune cells (ICs) in 46 cases of cSCC by immunohistochemistry. In each case, we employed two methods-intensity and proportion scores-to evaluate PD-L1 expression in TCs. For the evaluation of PD-L1 expression in ICs, only the proportion score was used. Association between PD-L1 expression and clinicopathological variables was analyzed using Fisher's exact test. RESULTS: High intensity scores in TCs were observed in 18 of the 46 cases (39.1%) and low intensity scores were observed in 28 cases (60.9%). Applying the proportions, using cut-off values of ≥1% and 50%, positive scores in TCs were observed in 36 (78.3%) and 20 cases (43.5%), respectively. PD-L1-positive ICs were observed in 29 (63%) and seven cases (15.2%), using cut-off values of ≥1% and 10%, respectively. The high intensity scores in TCs correlated with lymph node metastasis (P = 0.008) and female gender (P = 0.017), although positive proportions in TCs or ICs were not significantly related to lymph node metastasis. A multivariate analysis showed that high intensity of PD-L1 expression in TCs was an independent risk factor for lymph node metastasis. CONCLUSIONS: The results suggested that high intensity of PD-L1 expression in TCs is associated with lymph node metastasis in cSCC.

DOI： 10.1111/ajco.13102

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

In this case study, we aimed to evaluate the disease condition of patients with pustulotic arthro-osteitis (PAO) at 36-month post-tonsillectomy. A retrospective analysis of the cases of 17 patients with PAO who were resistant to initial systemic treatments and underwent tonsillectomy at our hospital in 2006-2016 was conducted. The patients' disease condition at 1-, 24-, and 36-month post-tonsillectomy was assessed by the visual analog scale (VAS) score for osteoarthropathic pain, the disease duration, the area of palmoplantar lesions, and the Palmoplantar Pustular Psoriasis Area Severity Index (ppPASI). In the minimum follow-up of 36-month post-tonsillectomy in 17 patients, the median ppPASI and VAS scores decreased from 12 to 1 and from 80 to 20, respectively. Thirteen patients with ≥70% improvement in their VAS scores maintained the same good condition after ≥36 months, whereas four patients with <70% improvement in their VAS scores did not show remarkable improvement after that time point. Furthermore, we found that the improvement in VAS score was not associated with the disease duration or the patients' pre-tonsillectomy ppPASI values. Tonsillectomy might be an alternative treatment option for patients with PAO. Long-term efficacy against pain can be predicted by evaluating a patient's improvement at 1-month post-tonsillectomy.

DOI： 10.5152/eurasianjmed.2019.19099

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Melanoma is one of the most lethal and malignant cancers and its incidence is increasing worldwide, and Japan is not an exception. Although there are numerous therapeutic options for melanoma, the prognosis is still poor once it has metastasized. The main concern after removal of a primary melanoma is whether it has metastasized, and early detection of metastatic melanoma would be effective in improving the prognosis of patients. Thus, it is very important to identify reliable methods to detect metastases as early as possible. Although many prognostic biomarkers (mainly for metastases) of melanoma have been reported, there are very few effective for an early diagnosis. Serum and urinary biomarkers for melanoma diagnosis have especially received great interest because of the relative ease of sample collection and handling. Several serum and urinary biomarkers appear to have significant potential both as prognostic indicators and as targets for future therapeutic methods, but still there are no efficient serum and urinary biomarkers for early detection, accurate diagnosis and prognosis, efficient monitoring of the disease and reliable prediction of survival and recurrence. Levels of 5-S-cysteinyldopa (5SCD) in the serum or urine as biomarkers of melanoma have been found to be significantly elevated earlier and to reflect melanoma progression better than physical examinations, laboratory tests and imaging techniques, such as scintigraphy and echography. With recent developments in the treatment of melanoma, studies reporting combinations of 5SCD levels and new applications for the treatment of melanoma are gradually increasing. This review summarizes the usefulness of 5SCD, the most widely used and well-known melanoma marker in the serum and urine, compares 5SCD and other useful markers, and finally its application to other fields.

DOI： 10.3390/ijms21020432

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Inflammatory bowel disease (IBD) is associated with a number of extraintestinal complications, including skin lesions. Most reports have shown that skin lesions are found in 10-15% of IBD cases, although this depends on the definition of skin lesions. The representative skin lesions in patients with IBD are erythema nodosum, pyoderma gangrenosum, Sweet's syndrome, and so on. These lesions are often associated with IBD progression, and intestinal lesions in particular require appropriate treatment. Recently, another clinical issue regarding skin lesions in patients with IBD, a so-called paradoxical reaction, during the treatment with anti-tumor necrosis factor (TNF)-α agents has emerged. These reactions are termed paradoxical reactions because the skin lesions sometimes resemble psoriasis, although the anti-TNF-α agents have been historically used to treat psoriasis. Paradoxical reactions are reportedly found in approximately 5-10% of patients using anti-TNF-α agents and are no longer rare. Now that the use of biologics is at its culmination, reports regarding paradoxical reactions are predicted to increase in number; thus, we must recognize skin lesions with IBD patients including this type of adverse events and manage them appropriately while consulting with dermatologists.

DOI： 10.1007/s12328-019-00958-y

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.15095

PubMed

Web of Science

researchmap

Language：English  

DOI： 10.1111/ajco.13139

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/1346-8138.14805

PubMed

Web of Science

researchmap

Language：English  

DOI： 10.1111/1346-8138.14596

PubMed

Web of Science

researchmap

DOI： 10.1111/jdv.15501

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.14549

PubMed

Web of Science

researchmap

Language：English  

DOI： 10.1016/j.jdcr.2018.08.012

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1002/cia2.12037

Web of Science

researchmap

Language：English  

DOI： 10.1684/ejd.2018.3381

PubMed

Web of Science

researchmap

Language：English  

DOI： 10.1684/ejd.2018.3375

PubMed

Web of Science

researchmap

Authorship：Corresponding author  

DOI： 10.1111/jdv.14927

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.14297

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.14287

PubMed

researchmap

Language：English   Publisher：Blackwell Publishing Ltd  

DOI： 10.1111/ijd.14004

PubMed

researchmap

Language：English   Publisher：Blackwell Publishing Ltd  

DOI： 10.1111/jdv.14845

researchmap

DOI： 10.1200/JCO.2018.36.15_suppl.e21603

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1001/jamadermatol.2017.6400

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/1346-8138.14170

PubMed

Web of Science

researchmap

Language：English  

A wide local excision is the standard treatment for extramammary Paget's disease (EMPD), though this treatment often leads to permanent anogenital mutilation and functional impairment. The purpose of our study is to evaluate the efficacy and safety of the topical application of imiquimod 5% cream for non-invasive EMPD. We examined nine patients with EMPD. Eight of the nine patients were treated with imiquimod 5% cream three times per week for 16 weeks; one case was treated for 6 weeks. The response rate was 100% including five complete remissions. Local irritation was observed in three patients, which was controlled by a provisional withdrawal of the treatment. These results suggest that imiquimod 5% cream may be considered an alternative therapeutic option for the treatment of non-invasive EMPD.

DOI： 10.1111/1346-8138.14117

PubMed

researchmap

Language：English  

There is no standard chemotherapeutic treatment for advanced extramammary Paget's disease, though the effectiveness of some chemotherapy regimens, including docetaxel, has been reported. In this report, we report that TS-1 monotherapy was effective in two patients with advanced extramammary Paget's disease after docetaxel treatment failure. TS-1 monotherapy may be useful as the second-line treatment for patients with advanced extramammary Paget's disease.

DOI： 10.1111/1346-8138.14017

PubMed

researchmap

Language：English  

DOI： 10.1111/1346-8138.14007

PubMed

Web of Science

researchmap

Authorship：Corresponding author   Language：English  

DOI： 10.1684/ejd.2017.3017

PubMed

Web of Science

researchmap

Language：English  

DOI： 10.1684/ejd.2017.2971

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/1346-8138.13760

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/1346-8138.13694

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1684/ejd.2016.2916

PubMed

Web of Science

researchmap

Language：English  

Because patients with xeroderma pigmentosum (XP) must avoid ultraviolet (UV) light from an early age, an early diagnosis of this disorder is essential. XP is composed of seven genetic complementation groups, XP-A to -G, and a variant type (XP-V). To establish an easy and accurate diagnosis of the eight disease groups, we constructed recombinant adenoviruses that expressed one of the XP cDNA. When fibroblasts derived from patients with XP-A, -B, -C, -D, -F or -G were infected with the adenovirus expressing XPA, XPB, XPC, XPD, XPF or XPG, respectively, and UV-C at 5-20 J/m2 was irradiated, cell viability was clearly recovered by the corresponding recombinant adenoviruses. In contrast, XP-E and XP-V cells were not significantly sensitive to UV irradiation and were barely complemented by the matched recombinant adenoviruses. However, co-infection of Ad-XPA with Ad-XPE increased survival rate of XP-E cells after UV-C exposure. When XP-V cell strains, including one derived from a Japanese patient, were infected with Ad-XPV, exposed to UV-B and cultured with 1 mmol/L of caffeine, flow cytometry detected a characteristic decrease in the S phase in all the XP-V cell strains. From these results, the eight groups of XP could be differentiated by utilizing a set of recombinant adenoviruses, indicating that our procedure provides a convenient and correct diagnostic method for all the XP groups including XP-E and XP-V.

DOI： 10.1111/1346-8138.13333

PubMed

researchmap

Language：English  

An ingredient of fruit polyphenol, resveratrol, is known to have an inhibitory effect on melanogenesis. In order to examine the functional differences between resveratrol and other fruit polyphenols, we compared biochemical effects of a resveratrol-free polyphenol, flavanol-rich lychee fruit extract (FRLFE), with other phenolic compounds including resveratrol. FRLFE as well as hydroquinone and resveratrol suppressed growth of B16F1 melanoma cells more significantly than rhododendrol or arbutin. Resveratrol suppressed mushroom tyrosinase at the lowest concentration (23.0 μmol/L) among the compounds tested. FRLFE and hydroquinone suppressed tyrosinase at almost the same concentration (half maximal inhibitory concentration [IC50 ], 83.5 and 94.6 μmol/L, respectively), which was higher than rhododendrol, ascorbic acid and arbutin (IC50 , 245, 345 and 421 μmol/L, respectively). Western blot analysis revealed that although resveratrol decreased expressions of tyrosinase and tyrosinase-related protein 1, FRLFE did not affect their expressions. Both FRLFE and resveratrol suppressed antimycin A-mediated reactive oxygen species (ROS) production in melanocytic cells. Resveratrol-mediated ROS suppression was inhibited by nicotinamide, a SIRT1 inhibitor. However, FRLFE-mediated suppression was not affected by nicotinamide. Moreover, FRLFE directly decreased superoxide in vitro, as detected by superoxide dismutase-like scavenging activity assay. These results suggest that FRLFE can protect melanocytes from cytotoxicity caused by an excess amount of melanin and ROS in a different manner from resveratrol.

DOI： 10.1111/1346-8138.13326

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

TNM staging is mainly used to evaluate the prognosis of melanoma patients. Serum biomarkers such as 5-S-cysteinyldopa (5-S-CD) have occasionally been used but most do not respond until the tumour burden becomes high. Recently, circulating melanoma cells (CMC) have been reported as a possible new biomarker to detect metastasis, monitor treatment response and predict prognosis. The object of this exploratory study was to evaluate the efficacy of CMC to detect metastasis and predict prognosis by cross-sectional and prospective observational analyses, respectively. Altogether 15 patients with stages II-IV melanoma were enrolled and CMC were enumerated by CellSearch system with cut-off values of two cells/7.5 mL. Serum 5-S-CD and lactate dehydrogenase (LDH) were also measured. The sensitivity of CMC and 5-S-CD for the detection of metastasis was 33 and 50%, respectively. The combination of CMC and 5-S-CD showed a sensitivity of 67%, the best performance among CMC, 5-S-CD, LDH and any combination of two of the markers. Additionally, a 30-month prospective observation showed that CMC could segregate patients with poorer prognosis. The median survival time for the patients with <2 CMC and those with ≥2 CMC was 19.5 and 4.5 months, respectively. The limitation of this study is the small sample size. These preliminary results indicate CMC may complement the efficacy of 5-S-CD to detect metastasis and can be a prognostic marker. Although there is still room for improvement to maximise the sensitivity, the CellSearch system is reproducible, standardised and suitable for multi-centre studies.

DOI： 10.1111/ajd.12455

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1684/ejd.2014.2515

PubMed

researchmap

Language：English  

DOI： 10.1111/ajd.12086

PubMed

Web of Science

researchmap

Language：English  

DOI： 10.1111/1346-8138.12652

PubMed

Web of Science

researchmap

Authorship：Corresponding author   Language：English  

DOI： 10.1111/1346-8138.12581

PubMed

Web of Science

researchmap

Language：English  

DOI： 10.1684/ejd.2014.2372

PubMed

Web of Science

researchmap

Language：English  

BACKGROUND: The age-adjusted incidence rate of prostate cancer (PCa) has been reported to be lower among Asians than Western populations. A traditional Japanese meal, high in soybean products or isoflavones, may be associated with a decreased risk of PCa. Equol, which is converted from daidzein by human intestinal flora, is biologically more active than any other isoflavone aglycone. MATERIALS AND METHODS: We reviewed not only recent epidemiological studies on association of isoflavones with PCa risk, but also recent research on human intestinal bacteria responsible for converting daidzein into equol. Studies were systematically searched from the database published within the last 5 years of from 2008-2012. RESULTS: Five out of 6 articles showed significant association of isoflavones with a decreased risk of PCa, and two of them consistently showed that equol-producers carry a significantly reduced risk of PCa. Furthermore, 5 human intestinal bacteria that can convert daidzein into equol were identified in the last 5 years. CONCLUSIONS: If equol can reduce risk of PCa, a possible strategy for reducing the risk of PCa may be to increase the proportion of equol-producers by changing the intestinal flora to carrying an equol-producing bacterium with dietary alteration or probiotic technology.

DOI： 10.7314/apjcp.2013.14.1.1

PubMed

researchmap

Authorship：Corresponding author   Language：English  

DOI： 10.1684/ejd.2012.1747

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1684/ejd.2011.1580

PubMed

Web of Science

researchmap

Language：English  

How melanosomal proteins such as enzymic proteins (tyrosinase and tyrosinase-related proteins, Tyrps) and structural protein (gp100) are transported from Golgi to melanosomal compartments is not yet fully understood. A number of small GTPases have been found to be associated with melanosomes and we have identified one of them, Rab7, a regulator of vesicular transport, organelle motility, phospholipid signaling and cytosolic degradative machinery, as being involved in the transport of Tyrp1 from Golgi to stage I melanosomes. This study further characterizes the role of Rab7 as a regulator of differential sorting of melanosomal proteins in this process. Murine melanocytes were transiently transfected with a plasmid encoding either wild-type (Rab7WT), constitutively active (Rab7Q67L) or dominant-negative (Rab7N125I and Rab7T22N) Rab7. Through immunocytostaining and confocal laser scanning microscopy, we quantitatively compared the bio-distribution of melanosomal proteins between Rab7WT-expressing cells and mutant Rab7-expressing cells. We also characterized their differential elimination from melanosomal compartments by Rab7 by utilizing a proteasome inhibitor, MG132. Our findings indicate that Rab7 plays an important role in differential sorting of tyrosinase, Tyrp1 and gp100 in early melanogenesis cascade, and that it is more specifically involved with Tyrp1 than tyrosinase and gp100 in the trafficking from Golgi to melanosomes and the specific exit from the degradative process.

DOI： 10.1111/j.1346-8138.2010.01004.x

PubMed

researchmap

Language：English  

Infundibulocystic basal cell carcinoma (IBCC) is a variant of basal cell carcinoma. Sporadic cases usually represent a solitary tumor and multiple IBCC is rare. There have been no reports in which the tumor differentiation is characterized immunohistochemically. We report a case of multiple IBCC which developed on a patient's scalp by performing histopathological and immunohistochemical examinations, using monoclonal antibodies against cytokeratins (CKs). A 76-year-old female had noticed multiple small papules on her scalp. She noticed that the tumors were growing when she underwent systemic chemotherapy for metastatic lung cancer. Routine histopathological specimens from skin biopsies revealed findings typical of IBCC. The tumor cells expressed CK14 and CK17. However, CK1 and CK10 were expressed only in a few cells in the inner area of the tumors. The present case is unique in two points. First, multiple tumors developed on the patient's scalp during the systemic chemotherapy for the lung cancer. Second, the tumor showed CK expression patterns characteristic to infundibular and trichilemmal epithelia.

DOI： 10.1111/j.1600-0560.2009.01451.x

PubMed

researchmap

Language：English  

Melanocortin-1 receptor (MC1R) and its ligands, alpha-melanocyte stimulating hormone (alphaMSH) and agouti signaling protein (ASIP), regulate switching between eumelanin and pheomelanin synthesis in melanocytes. Here we investigated biological effects and signaling pathways of ASIP. Melan-a non agouti (a/a) mouse melanocytes produce mainly eumelanin, but ASIP combined with phenylthiourea and extra cysteine could induce over 200-fold increases in the pheomelanin to eumelanin ratio, and a tan-yellow color in pelletted cells. Moreover, ASIP-treated cells showed reduced proliferation and a melanoblast-like appearance, seen also in melanocyte lines from yellow (A(y)/a and Mc1r(e)/ Mc1r(e)) mice. However ASIP-YY, a C-terminal fragment of ASIP, induced neither biological nor pigmentary changes. As, like ASIP, ASIP-YY inhibited the cAMP rise induced by alphaMSH analog NDP-MSH, and reduced cAMP level without added MSH, the morphological changes and depigmentation seemed independent of cAMP signaling. Melanocytes genetically null for ASIP mediators attractin or mahogunin (Atrn(mg-3J/mg-3J) or Mgrn1(md-nc/md-nc)) also responded to both ASIP and ASIP-YY in cAMP level, while only ASIP altered their proliferation and (in part) shape. Thus, ASIP-MC1R signaling includes a cAMP-independent pathway through attractin and mahogunin, while the known cAMP-dependent component requires neither attractin nor mahogunin.

DOI： 10.1111/j.1755-148X.2009.00582.x

PubMed

researchmap

Language：English  

Macrophage inhibitory cytokine-1 (MIC-1) is a divergent member of the TGF-beta superfamily. Although it has been reported to exhibit both tumorigenic and antitumorigenic activities, Boyle et al. report in this issue that MIC-1 expression was correlated with the tumorigenicity of melanoma cells. The elucidation of signaling pathways around MIC-1 might contribute to prospective targeting therapy for melanoma.

DOI： 10.1038/jid.2008.366

PubMed

researchmap

Language：English  

DOI： 10.1111/j.1365-4632.2009.03909.x

PubMed

researchmap

Language：English  

DOI： 10.1111/j.1468-3083.2006.01530.x

PubMed

Web of Science

researchmap

Language：English  

DOI： 10.1111/j.1468-3083.2006.01424.x

PubMed

Web of Science

researchmap

Language：English   Publisher：Sapporo Medical University  

researchmap

Language：English  

DOI： 10.1016/j.jss.2003.08.242

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/j.1067-1927.2004.012113.x

PubMed

Web of Science

researchmap

Language：English  

We report the case of a 12-year-old female patient who manifested multiple cutaneous angiomyxomas and labial pigmented lesions. Although the familial history was not confirmed in the present case, autosomal dominant inheritance has been reported to be involved in the pathogenesis of this condition. In addition to the cutaneous complications, magnetic resonance (MR) images revealed the presence of a pituitary adenoma, which provoked an elevation of serum growth hormone (GH) level. On the other hand, no significant symptoms such as cardiac myxoma, myxoid fibroadenoma of the breast, or adrenocortical complaints suggesting Cushing syndrome, were detected. In the Japanese literature, only a few cases of this disorder have been described in the form of brief reports. There have been only a few similar cases described in the dermatological field, except for one report diagnosed as Carney complex in 1990. Therefore, the present case seems to be the first Japanese case of typical Carney complex manifesting major clinical complications, including angiomyxomas, lentigines, and a pituitary adenoma, which induced endocrine overactivity.

DOI： 10.1111/j.1346-8138.2002.tb00225.x

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)癌と化学療法社  

Other Link:： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J00296&link_issn=&doc_id=20220425290008&doc_link_id=%2Fab8gtkrc%2F2022%2F004904%2F009%2F0409-0412%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2022%2F004904%2F009%2F0409-0412%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Ichushi

researchmap

Language：Japanese   Publisher：(株)協和企画  

Ichushi

researchmap

Language：Japanese   Publisher：(株)協和企画  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)医学書院  

Ichushi

researchmap

Language：Japanese   Publisher：(株)医学出版  

Ichushi

researchmap

Language：Japanese   Publisher：(株)学研メディカル秀潤社  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚科学会-西部支部  

Ichushi

researchmap

Language：Japanese   Publisher：日本レックリングハウゼン病学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚科学会-西部支部  

Ichushi

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本遺伝カウンセリング学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚科学会-西部支部  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚科学会-西部支部  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚科学会-西部支部  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚科学会-西部支部  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚病理組織学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(株)学研メディカル秀潤社  

Ichushi

researchmap

Language：Japanese   Publisher：日本レックリングハウゼン病学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

DOI： 10.18888/hi.0000000391

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本小児科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)日本臨床社  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本小児科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

DOI： 10.18888/hi.0000000353

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

DOI： 10.5227/skincancer.32.197

Ichushi

researchmap

Language：Japanese   Publisher：(株)協和企画  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚病理組織学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚病理組織学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

DOI： 10.18888/J01266.2016404555

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：日本レックリングハウゼン病学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

DOI： 10.14924/dermatol.125.419

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本レックリングハウゼン病学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚悪性腫瘍学会  

DOI： 10.5227/skincancer.29.12

Ichushi

researchmap

Language：Japanese   Publisher：日本遺伝カウンセリング学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)学研メディカル秀潤社  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

DOI： 10.14924/dermatol.123.2247

Ichushi

researchmap

Language：Japanese   Publisher：(株)日本臨床社  

Ichushi

researchmap

Language：Japanese   Publisher：(株)日本臨床社  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)医学書院  

DOI： 10.11477/mf.1412103712

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚アレルギー・接触皮膚炎学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床皮膚外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚悪性腫瘍学会  

DOI： 10.5227/skincancer.27.33

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚悪性腫瘍学会  

DOI： 10.5227/skincancer.27.107

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

DOI： 10.14924/dermatol.122.1375

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：国立病院総合医学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(株)東京医学社  

Ichushi

researchmap

Language：Japanese   Publisher：北海道医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚悪性腫瘍学会  

DOI： 10.5227/skincancer.26.85

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本皮膚悪性腫瘍学会  

DOI： 10.5227/skincancer.25.348

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床皮膚外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)日本臨床社  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床皮膚科医会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本創傷治癒学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床皮膚外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本臨床皮膚外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本創傷治癒学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本研究皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

Ichushi